Biweekly dose of TAS-102 reduces toxicity and remains effective for treatment of colorectal cancer, says study
Peer-Reviewed Publication
Updates every hour. Last Updated: 7-Nov-2025 08:10 ET (7-Nov-2025 13:10 GMT/UTC)
Immunotherapy is a revolutionary cancer treatment strategy that leverages the body’s immune system to fight cancer. While immune checkpoint inhibitors significantly improve the therapeutic outcomes in many tumors, most cancer patients cannot benefit from these.
Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control when compared to giving treatments over a longer period, according to breakthrough research led by the Universities of Sheffield and Leeds and Sheffield Teaching Hospitals NHS Foundation Trust.
Tests in 1,225 patients with the most deadly form of skin cancer reveal for the first time a genetic trait among most of those who did not respond to the latest cancer treatments, known as immune checkpoint inhibitors. Metastatic melanoma, as the disease is formally named, kills nearly 10,000 Americans annually.
Dysregulation of non-coding RNAs (ncRNAs) promotes pancreatic cancer growth, metastasis, treatment resistance, and cancer stemness. To shed light on the mechanisms behind their dysregulation, researchers from China, conducted a scientific review that summarizes how ncRNAs are involved in pancreatic cancer progression. Their study highlights that ncRNAs can act as scaffolds, promoting protein-protein/nucleotide interactions, as protein sponges that limit protein interactions, and by translocating proteins to various subcellular compartments.
Acute myeloid leukemia (AML) remains one of the most aggressive and deadly forms of blood cancer, even as treatments have advanced in recent years. Standard approaches like high-dose chemotherapy and bone marrow transplants can extend life but often come at the cost of severe side effects — and many patients still relapse due to drug-resistant cancer cells. A research team led by Natasha Kirienko at Rice University is working to change that by turning the cancer cells’ own energy systems against them.